URMC »Research » Research@URMC Blog

Featured Blog Post Image

Telomeres Might Predict Lung Cancer Recurrence

Telomeres are sections of DNA that tell an interesting story about lifespan. Shorter telomeres usually suggest a shorter life -- but new research by a Wilmot lung cancer expert shows that longer telomeres might be a promising biomarker for a recurrence of early stage lung cancer.

Female Fertility: What’s Testosterone Got To Do With It?

The use of testosterone to improve outcomes in women undergoing in vitro fertilization is taking hold across the country, but data on its use is slim and mixed. A new study suggests that male hormones might actually be doing something good. 

3/5/2014 | 1 comment

A Tumble, Thunk: How Serious is the Child’s Injury?

When a child wipes out while snowboarding or falls down a flight of stairs, paramedics quickly make triage decisions on site, including where to send the child for treatment. A Rochester team is studying thousands of these scenarios to learn the best practices at the scene, and what circumstances predict the need for a trauma center.

2/27/2014 | 0 comments

Local Charity Donates $75K to Wilmot Research

Did you see local TV cameras in the lobby of the Wilmot Cancer Center? The Pancreatic Cancer Association of Western New York (PCAWNY) presented a check for $75,176 for research at Wilmot, and three stations came out to film the check-passing event. The group raised the money at the 4th annual Step It Up to Cure Pancreatic Cancer 5K Walk last November.

2/26/2014 | 0 comments

Common Antidepressant Eases Agitation in Alzheimer’s Patients

Rochester researchers found that a high dose of a common antidepressant drug (citalopram) significantly reduced agitation in Alzheimer’s patients. Agitation is one of the most common reasons Alzheimer’s patients are moved out of their homes into higher levels of care. 

2/19/2014 | 0 comments

Wilmot Plays Role in Latest FDA-Approved CLL Therapy

This week the U.S. Food and Drug Administration expanded the use of the drug ibrutinib to treat patients who have chronic lymphocytic leukemia (CLL) – with UR Medicine’s James P. Wilmot Cancer Center participating in research that supported accelerated approval of the drug.

2/13/2014 | 0 comments